XCancer

First-in-human Study of Interferon-y PET Imaging to Assess Response to Immunotherapy

Description:

The goal of this clinical trial is to investigate the use of \[89Zr\]Zr-DFO-emapalumab as an IFN-γ PET imaging agent to detect lesions and response to therapy among treatment-naïve non-small cell lung cancer (NSCLC) patients. PET scans following the imaging agent will be completed prior to and about 30 days after starting immunotherapy.

Sponsor:

Barbara Ann Karmanos Cancer Institute

Phase:

Phase 1

Contacts:

Nerissa T Viola, PhD (PRINCIPAL_INVESTIGATOR)

Nerissa T Viola, PhD (CONTACT)

violan@karmanos.org

3135768309

Government Study Link:

NCT06439914 - Click here to see study on

ClinicalTrials.gov

DFO-emapalumab

Isotope(s):
Target(s):
  • IFN-γ
Ligand Class: Antibodies
Chelator: DFO